Invitae’s chromosomal microarray analysis (CMA) for pregnancy loss is DNA-based and delivers results in more than 92.4%1 of cases in as soon as 10-12 days, on average. No cell culture is required.
Approximately one in five clinically recognized pregnancies ends in miscarriage. Of first-trimester pregnancy losses, more than 50% are due to a fetal chromosomal abnormality.
Invitae testing can help determine the cause of second and third-trimester loss to give patients answers to their hardest question: why.
Better suited for the analysis of pregnancy loss tissue
Can be performed on formalin-fixed, paraffin-embedded samples
No cell culture required
Simultaneously detects maternal cell contamination without a maternal blood sample
Readily detects triploidy and molar pregnancies
Covers more bases to help prevent unnecessary testing
Allows for appropriate medical management and recurrence risk counseling
| Invitae’s microarray | Karyotyping | |
| Percentage of cases where results are obtained | >92.4%1 | 60-80%1-3 |
| Cell culture required | No (DNA-based) | Yes (frequent cell culture failure) |
| Can be performed on formalin-fixed, paraffin-embedded samples? | Yes | No |
| Detects submicroscopic gains and losses | Yes | No |
| Detects submicroscopic imbalances and molar pregnancy | Yes | No |
| Detects maternal cell contamination | Yes | No |
| Turnaround time | 10-12 days on average | ≥2 weeks (if culture is successful) |
In cases where collecting a fresh tissue sample is not an option, Invitae accepts formalin-fixed, paraffin-embedded samples.
Invitae technology provides superior, clinically focused, genome-wide coverage.
Invitae provides references to assist in patient counseling and links to tools for evaluating results.
Invitae’s laboratory directors have decades of experience in interpreting microarray results and can assist you in understanding complex results.
Invitae is proud to be in-network for more than 270 million patients, and to offer a financial assistance program for patients without coverage.
Invitae’s board-certified genetic counselors provide peer support for clinicians and post-test counseling for parents at no additional charge.
|
|
Request a free specimen collection kit online. |
|
|
Order a test using a paper test requisition form.
|
|
|
Receive a comprehensive results report
|
More than 9% of healthy adults have a genetic risk of developing cancer.
Cancer screening can offer healthy adults an opportunity to understand their DNA, assess heritable cancer risk, and take proactive action if necessary.
80% of children born with genetic disorders have no family history.
The American College of Obstetricians and Gynecologists (ACOG) recommends offering carrier screening to all patients of reproductive age, either before or during pregnancy.
Invitae NIPS can be performed as early as 10 weeks gestational age.
Invitae NIPS offers an industry-leading low test failure rate of <0.1% and offers 99% sensitivity and specificity for most chromosomes screened.
References:
